文献速递儿童青少年精神

全激酶组RNAi筛选鉴定ERK2为Shank3稳定性的可成药调控因子

A kinome-wide RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability.
PubMed 文献 · Mol Psychiatry · 2019-01-29

本研究通过全激酶组siRNA筛选寻找调控Shank3蛋白丰度的上游激酶,发现MEK/ERK2通路多个激酶可去稳定Shank3。遗传缺失或药理抑制ERK2可在体内增加Shank3丰度;ERK2结合Shank3并磷酸化其三个残基,促进多泛素化依赖的降解。

要点

  • 全激酶组siRNA筛选鉴定出多个潜在调控Shank3蛋白稳定性的激酶。
  • ERK2遗传缺失或药理抑制可在体内增加Shank3丰度。
  • ERK2结合Shank3并磷酸化三个残基,促进其多泛素化依赖降解。

核心结论

  • ERK2是Shank3蛋白稳定性的上游负调控因子,抑制ERK2可增加Shank3丰度。
  • MEK/ERK2通路可作为SHANK3剂量不足相关疾病的潜在治疗靶点。

研究设计与样本

  • 研究采用全激酶组siRNA筛选,鉴定调控Shank3蛋白稳定性的激酶。
  • 通过遗传缺失和药理抑制ERK2在体内验证其对Shank3丰度的影响。

主要发现

  • 全激酶组siRNA筛选发现MEK/ERK2通路多个激酶可去稳定Shank3。
  • ERK2遗传缺失和药理抑制均增加体内Shank3丰度。
  • ERK2结合Shank3并磷酸化其三个残基,促进多泛素化依赖的降解。

临床怎么用

  • 针对SHANK3单倍剂量不足相关疾病,抑制ERK2可能通过提升Shank3水平发挥治疗作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neurons are sensitive to changes in the dosage of many genes, especially those regulating synaptic functions. Haploinsufficiency of SHANK3 causes Phelan-McDermid syndrome and autism, whereas duplication of the same gene leads to SHANK3 duplication syndrome, a disorder characterized by neuropsychiatric phenotypes including hyperactivity and bipolar disorder as well as epilepsy. We recently demonstrated the functional modularity of Shank3, which suggests that normalizing levels of Shank3 itself might be more fruitful than correcting pathways that function downstream of it for treatment of disorders caused by alterations in SHANK3 dosage. To identify upstream regulators of Shank3 abundance, we performed a kinome-wide siRNA screen and identified multiple kinases that potentially regulate Shank3 protein stability. Interestingly, we discovered that several kinases in the MEK/ERK2 pathway destabilize Shank3 and that genetic deletion and pharmacological inhibition of ERK2 increases Shank3 abundance in vivo. Mechanistically, we show that ERK2 binds Shank3 and phosphorylates it at three residues to promote its poly-ubiquitination-dependent degradation. Altogether, our findings uncover a druggable pathway as a potential therapeutic target for disorders with reduced SHANK3 dosage, provide a rich resource for studying Shank3 regulation, and demonstrate the feasibility of this approach for identifying regulators of dosage-sensitive genes.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Wang L, Adamski CJ, Bondar VV, et al. A kinome-wide RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability. Mol Psychiatry. 2019. PMID: 30696942. doi:10.1038/s41380-018-0325-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。